Ardelyx Inc.

236 articles about Ardelyx Inc.

• Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that a webcast of Mike Raab , president and chief executive officer of Ardelyx, and Susan Rodriguez , chief commercial offic

• Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

  11/10/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtu

• Ardelyx to Webcast Virtual Analyst Day

  11/6/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on Thursday, November 12, 2020, from 9:30 a.m. to 12:00 p.m. ET.

• Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights

  11/5/2020

  Ardelyx Inc.  (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results for the third quarter ended September 30, 2020.

• Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

  10/22/2020

  --Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia--

• Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020

  10/12/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases

• Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

  9/15/2020

  NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy PDUFA Goal Date - April 29, 2021   [15-September-2020]   FREMONT, Calif. , Sept. 15, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people w

• Ardelyx to Participate in Three Upcoming Investor Conferences in September

  9/8/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Ardelyx management will participate in three upcoming investor conferences in September including:

• Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights

  8/6/2020

  Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments

• Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

  8/3/2020

  A New Drug Application for the Review of Tenapanor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis has Been Submitted to the FDA

• Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

  6/30/2020

  Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis

• Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis

  6/15/2020

  Foundational use of tenapanor as monotherapy or with sevelamer enabled up to 47.4% of patients to achieve normal serum phosphorus levels (<4.6 mg/dL), a 58% improvement over current standard of care NDA submission for tenapanor for the control of serum phosphorus on-track for mid-2020 Separately, Ardelyx's tenapanor partner in Japan, Kyowa Kirin, presented Phase 2 data at ERA-EDTA demonstrating tenapanor enabled a significant reduction in overall pill burden (mean reductio

• Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 10, 2020

  6/10/2020

  Ardelyx, Inc. announced that on June 8, 2020, the compensation committee of the Company's Board of Directors granted a non-qualified stock option award to purchase 195,017 shares of its common stock and a restricted stock unit award for 10,000 shares in connection with the commencement of employment of its new Chief Financial Officer, Justin Renz

• Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

  6/8/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to the position of Chief Financial Officer.

• Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies

• Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  5/21/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on  May 18, 2020,

• Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

  5/18/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez, an industry veteran with over 25 years of global pharmaceutical experience, as the company's first chief commercial officer.

• Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

  5/7/2020

  Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments

• Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

  3/16/2020

  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the Company's Board of Directors

• Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

  3/6/2020

  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019 .